webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

BCN-PEG4-NHS ester

  CAS No.: 1702356-19-1   Cat No.: BADC-00415   Purity: ≥98% 4.5  

BCN-PEG4-NHS ester is a click chemistry-enabled linker for strain-promoted azide-alkyne cycloaddition (SPAAC). Ideal for bioconjugation in ADCs without copper catalysis.

BCN-PEG4-NHS ester

Structure of 1702356-19-1

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C26H38N2O10
Molecular Weight
538.59
Shipping
Room temperature
Shipping
Please store the product under the recommended conditions in the Certificate of Analysis.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
50 mg $629 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
BCN-endo-PEG4-NHS; BCN-endo-PEG4-SPA; BCN-exo-PEG4-NHS; rel-2,5-Dioxopyrrolidin-1-yl 1-((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13,16-pentaoxa-4-azanonadecan-19-oate
IUPAC Name
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[[(1S,8R)-9-bicyclo[6.1.0]non-4-ynyl]methoxycarbonylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
Canonical SMILES
C1CC2C(C2COC(=O)NCCOCCOCCOCCOCCC(=O)ON3C(=O)CCC3=O)CCC#C1
InChI
InChI=1S/C26H38N2O10/c29-23-7-8-24(30)28(23)38-25(31)9-11-33-13-15-35-17-18-36-16-14-34-12-10-27-26(32)37-19-22-20-5-3-1-2-4-6-21(20)22/h20-22H,3-19H2,(H,27,32)/t20-,21+,22?
InChIKey
MFQCOKMBYCIQEJ-CBQGHPETSA-N
Density
1.28±0.1 g/cm3
Appearance
Soild powder
Shipping
Room temperature
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.

BCN-PEG4-NHS ester, a versatile bifunctional crosslinking reagent, plays a pivotal role in bioconjugation and chemical biology. Explore its diverse applications presented with a high degree of perplexity and burstiness:

Protein Labeling: An indispensable tool for scientists, BCN-PEG4-NHS ester is harnessed for the covalent attachment of fluorescent dyes, enzymes, or other biomolecules to proteins. This strategic modification facilitates in-depth exploration of protein dynamics, localization, and interactions through cutting-edge techniques like fluorescence microscopy. The conjugation with BCN-PEG4-NHS ester not only ensures the preservation of biological activity but also enhances the solubility of the labeled proteins, opening new avenues in protein research.

Drug Delivery Systems: Enter the realm of targeted drug delivery systems empowered by BCN-PEG4-NHS ester. By conjugating drugs with specific targeting ligands, such as antibodies or peptides, using this versatile reagent, researchers orchestrate precise delivery of therapeutic agents to designated cells or tissues. This tailored approach not only amplifies the drug’s efficacy but also mitigates off-target effects.

Surface Modification: Witness the transformative power of BCN-PEG4-NHS ester in surface functionalization of nanoparticles, biomaterials, and sensors. The innate chemical groups of this reagent facilitate seamless covalent attachment of biomolecules, elevating the biocompatibility and functionality of the modified surfaces. This pivotal role is instrumental in crafting cutting-edge biosensors, medical implants, and diagnostic devices that boast enhanced performance and reliability.

Click Chemistry: Step into the realm of bio-orthogonal ‘click’ chemistry reactions, where BCN-PEG4-NHS ester shines as a key player. Its efficient reactivity with azide-functionalized molecules forms stable triazole linkages, enabling the assembly of intricate bioconjugates under mild conditions. This innovative application holds immense value in constructing multifunctional biomolecules tailored for research endeavors and therapeutic interventions, propelling scientific discovery and medical advancements to new heights.

1. Catalytic antibodies
R A Lerner, K D Janda, A Tramontano Science . 1986 Dec 19;234(4783):1566-70. doi: 10.1126/science.3787261.
Monoclonal antibodies elicited to haptens that are analogs of the transition state for hydrolysis of carboxylic esters behaved as enzymic catalysts with the appropriate substrates. These substrates are distinguished by the structural congruence of both hydrolysis products with haptenic fragments. The haptens were potent inhibitors of this esterolytic activity, in agreement with their classification as transition state analogs. Mechanisms are proposed to account for the different chemical behavior of these antibodies with two types of ester substrates. The generation of an artificial enzyme through transition state stabilization by antibodies was thus demonstrated. These studies indicate a potentially general approach to catalyst design.
2. [Esters and stereoisomers]
C Diefenbach, V Nigrovic, H Mellinghoff Anaesthesist . 1997 Apr;46(4):282-6. doi: 10.1007/s001010050402.
This review discusses concepts of isomers, stereoisomers, chirality, and enantiomers as applied to drugs used in anaesthesia. The inhalational anaesthetics enflurane and isoflurane are examples of stereoisomers. A chiral centre is formed when a carbon or quaternary nitrogen atom is connected to four different atoms. A molecule with one chiral centre is then present in one of two possible configurations termed enantiomers. A racemate is a mixture of both enantiomers in equal proportions. Many of the drugs used in anaesthesia are racemic mixtures (the inhalation anaesthetics, local anaesthetics, ketamine, and others). The shape of the atracurium molecule is comparable to that of a dumb-bell:the two isoquinoline groups representing the two bulky ends connected by an aliphatic chain. In each isoquinoline group there are two chiral centres, one formed by a carbon and the other by a quaternary nitrogen atom. From a geometric point of view, the connections from the carbon atom to a substituted benzene ring and from the quaternary nitrogen to the aliphatic chain may point in the same direction (cis configuration) or in opposite directions (trans configuration). The two isoquinoline groups in atracurium are paired in three geometric configurations: cis-cis, trans-trans, or cis-trans. However, the two chiral centres allow each isoquinoline group to exist in one of four stereoisometric configurations. In the symmetrical atracurium molecule, the number of possible stereoisomers is limited to ten. Among these, 1 R-cis, 1'R-cis atracurium was isolated and its pharmacologic properties studied. This isomer, named cis-atracurium, offers clinical advantages over the atracurium mixture, principally due to the lack of histamine-releasing propensity and the higher neuromuscular blocking potency. The ester groups appear in one of two steric configurations true and reverse esters. In the true esters, oxygen is positioned between the nitrogen atom and the carbonyl group, while in the reverse esters in its positioned on the other side of the carbonyl group. True esters, suxamethonium and mivacurium, are hydrolysed by the enzyme plasma cholinesterase (butyrylcholinesterase), albeit at different rates. The more rapid degradation of suxamethonium is responsible for its fast onset and short duration of action in comparison with mivacurium. The reverse esters, atracurium, cisatracurium, and remifentanil, are hydrolysed by nonspecific esterases in plasma (carboxyesterases). Remifentanil is hydrolysed rapidly; the degradation leads to its inactivation and short duration of action. Cis-atracurium is preferentially degraded and inactivated by a process known as Hofmann elimination. In a second step, one of the degradation products, the monoester acrylate, is hydrolysed by a nonspecific esterase.
3. Lactose esters: synthesis and biotechnological applications
Maciej Guzik, Ewelina Cichoń, Janusz M Dąbrowski, Jakub Staroń Crit Rev Biotechnol . 2018 Mar;38(2):245-258. doi: 10.1080/07388551.2017.1332571.
Biodegradable nonionic sugar esters-based surfactants have been gaining more and more attention in recent years due to their chemical plasticity that enables the various applications of these molecules. In this review, various synthesis methods and biotechnological implications of lactose esters (LEs) uses are considered. Several chemical and enzymatic approaches are described for the synthesis of LEs, together with their applications, i.e. function in detergents formulation and as additives that not only stabilize food products but also protect food from undesired microbial contamination. Further, this article discusses medical applications of LEs in cancer treatment, especially their uses as biosensors, halogenated anticancer drugs, and photosensitizing agents for photodynamic therapy of cancer and photodynamic inactivation of microorganisms.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Polatuzumab vedotin | PTAD-PEG4-amine | 1-(4-((5-(dimethylcarbamoyl)pyridin-2-yl)disulfanyl)butanoyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid | 5-azidopentanoic acid N-hydroxysuccinimide ester | 6-O-2-Propyn-1-yl-D-galactose | MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA | N-succinimidyl 4-(5-nitro-pyridin-2-yldithio)-pentanoate | SPDB-DM1 | SMPT | Mal-PEG2-Val-Cit-PABA | BCN-PEG4-NHS ester
Send Inquiry
Verification code
Inquiry Basket